Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 15

PMID 33718206

Citations 11

Authors

Xiaofei Zhang

Wenjun Zhang

Pingan Cao

Affiliations

Soon will be listed here.

Abstract

With the aging of the population, the incidence of colorectal cancer in China is increasing. One of the epigenetic alterations: CpG island methylator phenotype (CIMP) plays an important role in the incidence of colorectal cancer. Recent studies have shown that CIMP is closely related to some specific clinicopathological phenotypes and multiple molecular phenotypes in colorectal cancer. In this paper, the newest progress of CIMP colorectal cancer in chemotherapeutic drugs, targeted agents and small molecular methylation inhibitors are going to be introduced. We hope to provide potential clinical treatment strategies for personalized and precise treatment of colorectal cancer patients.

Citing Articles

Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance.

Duta-Ion S, Juganaru I, Hotinceanu I, Dan A, Burtavel L, Coman M Int J Mol Sci. 2024; 25(23).

PMID: 39684219 PMC: 11641537. DOI: 10.3390/ijms252312507.

Deep learning-based histological predictions of chromosomal instability in colorectal cancer.

Hyeon D, Kim Y, Hwang Y, Bae J, Kang G, Kim K Am J Cancer Res. 2024; 14(9):4495-4505.

PMID: 39417190 PMC: 11477831. DOI: 10.62347/JYND6488.

Unmasking early colorectal cancer clues: in silico and in vitro investigation of downregulated IGF2, SOCS1, MLH1, and CACNA1G in SSA polyps.

Mirbahari S, Fatemi N, Savabkar S, Chaleshi V, Zali N, Taleghani M Mol Biol Rep. 2024; 51(1):764.

PMID: 38874740 PMC: 11178608. DOI: 10.1007/s11033-024-09683-3.

Hypermethylated Colorectal Cancer Tumours Present a Myc-Driven Hypermetabolism with a One-Carbon Signature Associated with Worsen Prognosis.

Desterke C, Jaulin F, Dornier E Biomedicines. 2024; 12(3).

PMID: 38540202 PMC: 10968523. DOI: 10.3390/biomedicines12030590.

Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.

Serrao E, Klug M, Moloney B, Jhaveri A, Gullo R, Pinker K Radiol Imaging Cancer. 2023; 5(6):e220153.

PMID: 37921555 PMC: 10698595. DOI: 10.1148/rycan.220153.

References

Cha Y, Kim K, Han S, Rhee Y, Bae J, Wen X . Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer. 2016; 115(2):164-71. PMC: 4947699. DOI: 10.1038/bjc.2016.176. View

Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K . CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. Int J Clin Oncol. 2016; 21(6):1091-1101. DOI: 10.1007/s10147-016-1017-6. View

Bae J, Kim J, Kwak Y, Lee D, Cha Y, Wen X . Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. Br J Cancer. 2017; 116(8):1012-1020. PMC: 5396110. DOI: 10.1038/bjc.2017.52. View

Juo Y, Johnston F, Zhang D, Juo H, Wang H, Pappou E . Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014; 25(12):2314-2327. PMC: 4239805. DOI: 10.1093/annonc/mdu149. View

Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B . CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003; 9(8):2898-903. View

Okugawa Y, Grady W, Goel A . Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology. 2015; 149(5):1204-1225.e12. PMC: 4589488. DOI: 10.1053/j.gastro.2015.07.011. View

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R . Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Ann Oncol. 2018; 29(8):1800-1806. DOI: 10.1093/annonc/mdy197. View

Azad N, El-Khoueiry A, Yin J, Oberg A, Flynn P, Adkins D . Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017; 8(21):35326-35338. PMC: 5471058. DOI: 10.18632/oncotarget.15108. View

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C . Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. Clin Cancer Res. 2018; 24(19):4745-4753. DOI: 10.1158/1078-0432.CCR-18-0866. View

10.

Han S, Lee H, Bae J, Cho N, Lee K, Kim T . Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer. 2012; 132(9):2209-16. DOI: 10.1002/ijc.27888. View

11.

Furtado C, Luciano M, da Silva Santos R, Furtado G, Moraes M, Pessoa C . Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019; 14(12):1164-1176. PMC: 6791710. DOI: 10.1080/15592294.2019.1640546. View

12.

Shen L, Catalano P, Benson 3rd A, ODwyer P, Hamilton S, Issa J . Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 2007; 13(20):6093-8. PMC: 3575642. DOI: 10.1158/1078-0432.CCR-07-1011. View

13.

Cohen S, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G . Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. Clin Colorectal Cancer. 2015; 15(2):164-9. PMC: 4864501. DOI: 10.1016/j.clcc.2015.10.005. View

14.

Garrido-Laguna I, McGregor K, Wade M, Weis J, Gilcrease W, Burr L . A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs. 2013; 31(5):1257-64. DOI: 10.1007/s10637-013-9947-6. View

15.

Bonasio R, Tu S, Reinberg D . Molecular signals of epigenetic states. Science. 2010; 330(6004):612-6. PMC: 3772643. DOI: 10.1126/science.1191078. View

16.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

17.

Sasidharan Nair V, Toor S, Taha R, Shaath H, Elkord E . DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics. 2018; 10(1):104. PMC: 6080402. DOI: 10.1186/s13148-018-0539-3. View

18.

Calegari M, Inno A, Monterisi S, Orlandi A, Santini D, Basso M . A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer. 2017; 116(10):1279-1286. PMC: 5482728. DOI: 10.1038/bjc.2017.109. View

19.

Tsai H, Li H, Van Neste L, Cai Y, Robert C, Rassool F . Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012; 21(3):430-46. PMC: 3312044. DOI: 10.1016/j.ccr.2011.12.029. View

20.

Lange C, Laird P . Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics. 2013; 5(2):105-8. DOI: 10.2217/epi.13.4. View